Home › Pancreatic Cancer › NCT07542041
Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens
Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens (ANoPs)
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Age ≥ 18 years * Ability to understand and willingness to sign a written informed consent form * Clinical indication for fine needle biopsy (FNB) of a suspicious pancreatic lesion accessible for biopsy Exclusion Criteria: * Any condition that, in the opinion of the investigator, makes the subject unsuitable for participation in the study
About the study
The goal of this clinical study is to evaluate whether the NEO-Match® test, based on ARTIDIS nanomechanical profiling technology, can help predict treatment outcomes and improve clinical decision-making in patients with suspected pancreatic cancer undergoing biopsy.
The main questions this study aims to answer are:
* Can the NEO-Match® test predict how patients respond to neoadjuvant (pre-surgical) treatment for pancreatic cancer? * How well does the NEO-Match® test detect malignant pancreatic lesions compared to standard histopathological assessment?
This is a prospective, single-arm study. Researchers will compare results from the NEO-Match® test with standard clinical outcomes, imaging findings, and pathology results to evaluate its predictive and diagnostic performance.
Participants will:
* Undergo a standard-of-care pancreatic biopsy or surgical procedure * Provide an additional biopsy sample for research analysis using the ARTIDIS ART-1 device * Continue to receive standard treatment and care, which is not influenced by the study * Have clinical data, imaging results, and treatment outcomes collected * Be followed every 3 months for up to 2 years
The study does not involve experimental treatment or changes to standard medical care. The information collected may help improve future diagnosis, prognosis, and treatment selection for patients with pancreatic cancer.
What is being tested
- ARTIDIS ART-1 Device (device)
Sponsor: ARTIDIS AG · Participants: 200 · Started: Apr 17, 2026
Contact the study team
- Julia Ortega, DMSc, MHS, PA · Phone: 2404980176
Official record on ClinicalTrials.gov — NCT07542041
Locations in the U.S.
| Florida | Moffitt Cancer Center, Tampa |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.